publication . Article . 2001

Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly

Drake, W. M.; Parkinson, C.; Besser, G. M.; Peter Trainer;
  • Published: 01 Nov 2001 Journal: Trends in Endocrinology and Metabolism, volume 12, pages 408-413 (issn: 1043-2760, Copyright policy)
  • Publisher: Elsevier BV
The elucidation of the mechanisms by which growth hormone (GH) interacts with its receptor has facilitated the design of compounds that function as GH-receptor antagonists. One such compound, B2036, has been conjugated to polyethylene glycol to produce a drug, pegvisomant, that has a powerful ability to lower circulating concentrations of insulin-like growth factor I (IGF-I), the principal mediator of GH action, in patients with acromegaly and to improve the symptoms and signs associated with GH excess. This article describes the mechanism of action of GH-receptor antagonists, reviews the preclinical and clinical data on the use of pegvisomant and discusses some...
free text keywords: Endocrinology, Diabetes and Metabolism, Endocrinology
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue